Pulse lineResearch With Heart Logo

Association of Proton Pump Inhibitors With Higher Risk of Cardiovascular Disease and Heart Failure.

TitleAssociation of Proton Pump Inhibitors With Higher Risk of Cardiovascular Disease and Heart Failure.
Publication TypeJournal Article
Year of Publication2021
AuthorsBell EJ, Bielinski SJ, St Sauver JL, Chen LY, Rooney MR, Larson NB, Takahashi PY, Folsom AR
JournalMayo Clin Proc
Volume96
Issue10
Pagination2540-2549
Date Published2021 10
ISSN1942-5546
KeywordsAfrican Americans, Aged, Cardiovascular Diseases, Cohort Studies, Female, Heart Failure, Humans, Male, Proton Pump Inhibitors, Risk Assessment, Risk Factors, United States, Whites
Abstract

OBJECTIVE: To examine associations of cumulative exposure to proton pump inhibitors (PPIs) with total cardiovascular disease (CVD; composed of stroke, coronary heart disease, and heart failure [HF]) and HF alone in a cohort study of White and African American participants of the Atherosclerosis Risk in Communities (ARIC) study.

METHODS: Use of PPIs was assessed by pill bottle inspection at visit 1 (January 1, 1987 to 1989) and up to 10 additional times before baseline (visit 5; 2011 to 2013). We calculated cumulative exposure to PPIs as days of use from visit 1 to baseline. Participants (n=4346 free of total CVD at visit 5; mean age, 75 years) were observed for incident total CVD and HF events through December 31, 2016. We used Cox regression to measure associations of PPIs with total CVD and HF.

RESULTS: After adjustment for potential confounding variables, participants with a cumulative exposure to PPIs of more than 5.1 years had a 2.02-fold higher risk of total CVD (95% CI, 1.50 to 2.72) and a 2.21-fold higher risk of HF (95% CI, 1.51 to 3.23) than nonusers.

CONCLUSION: Long-term PPI use was associated with twice the risk of total CVD and HF compared with nonusers. Our findings are in concordance with other research and suggest another reason to be cautious of PPI overuse.

DOI10.1016/j.mayocp.2021.02.025
Alternate JournalMayo Clin Proc
PubMed ID34607633
PubMed Central IDPMC8631442
Grant ListHHSN268201000013C / HL / NHLBI NIH HHS / United States
T32 HL007111 / HL / NHLBI NIH HHS / United States
HHSN268201700001I / HL / NHLBI NIH HHS / United States
HHSN268201700004I / HL / NHLBI NIH HHS / United States
HHSN268201000015C / HL / NHLBI NIH HHS / United States
HHSN268201700004C / HL / NHLBI NIH HHS / United States
HHSN268201700003I / HL / NHLBI NIH HHS / United States
T32 HL007779 / HL / NHLBI NIH HHS / United States
HHSN268201700002C / HL / NHLBI NIH HHS / United States
HHSN268201700005C / HL / NHLBI NIH HHS / United States
HHSN268201700001C / HL / NHLBI NIH HHS / United States
HHSN268201700003C / HL / NHLBI NIH HHS / United States
HHSN268201700002I / HL / NHLBI NIH HHS / United States
HHSN268201700005I / HL / NHLBI NIH HHS / United States